December 17, 2021 10:59 AM EST
News Briefing

Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

Paul Schloesser

Associate Editor

Well, Pur­due Phar­ma’s mul­ti-bil­lion dol­lar opi­oid set­tle­ment is now in jeop­ardy — a fed­er­al judge just said no.

Colleen McMa­hon, a judge on the US Dis­trict …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times